SCHEMBL2341920

SCHEMBL2341920

Cc1cccc(-n2c(Cl)c(C=O)c3ccccc32)c1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 6/20 0.48
NPSR1 Q6W5P4 5/20 0.48
HTT P42858 5/20 0.48
HPGD P15428 1/20 0.48
TP53 P04637 1/20 0.39
MAT2A P31153 1/20 0.39
SMN1; SMN2 Q16637 2/20 0.39
POLB P06746 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.39
PMM2 O15305 1/20 0.39
MPI P34949 1/20 0.39
PHOSPHO1 Q8TCT1 1/20 0.39
ALDH1A1 P00352 2/20 0.39
MEN1 O00255 1/20 0.39
USP2 O75604 1/20 0.39
KMT2A Q03164 1/20 0.39
LMNA P02545 2/20 0.39
ATM Q13315 1/20 0.39
NOD2 Q9HC29 1/20 0.39
KDM4E B2RXH2 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2345291 0.87 NPSR1 (0.44) MAPTNPSR1HTTSMN1; SMN2POLB
SCHEMBL2343332 0.84 FGFR1 (0.45) MAPTNPSR1HTTHPGDSMN1; SMN2
SCHEMBL2348488 0.84 MAPT (0.48) MAPTNPSR1HTTHPGDSMN1; SMN2
SCHEMBL2348590 0.84 CYP1A2 (0.46) NPSR1HTTHPGDTP53SMN1; SMN2
SCHEMBL29954953 0.84 KDM4E (0.52) MAPTNPSR1HTTSMN1; SMN2POLB
SCHEMBL2343158 0.84 KDM4E (0.52) MAPTNPSR1HTTSMN1; SMN2POLB
SCHEMBL2343043 0.83 MAT2A (0.39) MAPTNPSR1HTTHPGDMAT2A
SCHEMBL2351229 0.83 MEN1 (0.42) MAPTNPSR1HTTMAT2ASMN1; SMN2
SCHEMBL2349748 0.82 KMT2A (0.39) MAPTHTTHPGDTP53MAT2A
SCHEMBL2342751 0.81 MEN1 (0.42) MAPTNPSR1TP53SMN1; SMN2POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8008491-B2 poly(adenosine 5'-diphosphate ribose) polymerase inhibitors such as 1-phenyl-2-(piperazin-1-yl)-1,3-dihydropyrrolo[2,3-b]pyridine-3-carboxaldehyde, used in the treatment and/or prevention central nervous system and cardiovascular disorders AVENTIS PHARMACEUTICALS, INC. (US) 2011-08-30 US disclosed
US-20080255350-A1 SUBSTITUTED AZA-INDOLES AS INHIBITORS OF POLY(ADP-RIBOSE) POLYMERASE (PARP) AVENTIS PHARMACEUTICALS INC. (US) 2008-10-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080255350-A1 SUBSTITUTED AZA-INDOLES AS INHIBITORS OF POLY(ADP-RIBOSE) POLYMERASE (PARP) PARP1, PARP11, PARP15 MAPT 3033/4885NPSR1 650/4885HTT 626/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.